Razazian N, Sahraian M, Eskandarieh S, Jafari N, Rezaei M, Fakhri N. Follow-up of Patients With Multiple Sclerosis After COVID-19 Vaccination With Sinopharm Vaccine. Caspian J Neurol Sci 2023; 9 (4) :244-251
URL:
http://cjns.gums.ac.ir/article-1-666-en.html
1- Department of Neurology, Neuroscience Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
3- Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
Abstract: (294 Views)
Background: Vaccination against COVID-19 for people with multiple sclerosis (PWMS) has been
recommended, but long-term follow-up needs further research.
Objectives: To follow up PWMS 3 months after vaccination with the Sinopharm vaccine regarding
the relapse of MS and infection with COVID-19.
Materials & Methods: The participants in this prospective study were PWMS over 18 years
of age living in Kermanshah Province, Iran, who received two doses of the Sinopharm vaccine
between August and November 2021. The information on demographic and clinical characteristics
of PWMS, COVID-19 infection, and relapses of MS 3 months after vaccination, were collected. We
contacted the patients using the information registered in the MS registry system of Kermanshah
Province, and the study data were collected by phone call and using a researcher-made questionnaire.
Results: Overall, 197 MS patients with a Mean±SD age of 41.84±11.0 years, including 155(78.7%) females
and 42(21.3%) males were studied. There was no significant difference (P=1.000) in MS relapse frequency
between the time points of 3 months before the first dose (15[7.6%]) and 3 months after the second dose
(15[7.6%]). The frequency of infection with COVID-19 within 3 months after the second dose (26[13.2%])
was significantly (P=0.017) higher than that in the 3 months before the first dose (12[6.1%]). Within 3 months
after the second dose, most PWMS with MS relapse or COVID-19 infection used oral and anti-CD20 therapy.
Conclusion: During the 3 months after the second dose, the frequency of MS relapse was not
different, but the frequency of COVID-19 infection was higher.
Full-Text [PDF 1136 kb]
(123 Downloads)
| |
Full-Text (HTML) (71 Views)
• Multiple sclerosis relapse frequency did not differ significantly before and after the vaccination.
• Infection of COVID-19 was higher three months after vaccination than before that.
• The majority of people with multiple sclerosis who had relapsed after vaccination, had motor and sensory symptoms.
• A small percentage of people with multiple sclerosis who had the infection after vaccination, had severe symptoms.
Type of Study:
Research |
Subject:
Special Received: 2023/10/11 | Accepted: 2023/10/17 | Published: 2023/10/17